Osteoporotic fracture and parathyroid hormone

doi:10.5312/wjo.v2.i8.67

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6989)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

461

HTML

5897

Figures (1-2)

631

Sum=6989

Aug 18, 2011 (publication date) through Dec 14, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Orthop. Aug 18, 2011; 2(8): 67-74
Published online Aug 18, 2011. doi: 10.5312/wjo.v2.i8.67

Full Size Figure Download Figure

Figure 1 Current and future therapies for osteoporotic fractures[107-109]. SERMs: Selective estrogen receptor modulators; RANKL: Ab-receptor activator of nuclear factor ЌB antibody; Wnt: Wingless signaling pathway; CAM: Cell adhesion molecules; IGF: Insulin growth factor, LC: L-carnitine; Iso-V-LC: Isovaleryl-L-carnitine; MMP: Matrix metalloproteinase; PTH: Parathyroid hormone; LRP: LDL receptor related protein receptor; SARM: Selective androgen receptor modulators.

Citation: Datta NS. Osteoporotic fracture and parathyroid hormone. World J Orthop 2011; 2(8): 67-74
URL: https://www.wjgnet.com/2218-5836/full/v2/i8/67.htm
DOI: https://dx.doi.org/10.5312/wjo.v2.i8.67